Introduction {#S1}
============

Hantavirus pulmonary syndrome (HPS) is a severe life threatening disease caused by members of the genus *Hantavirus*. In the United States, these members include Sin Nombre virus, Bayou virus, Black Creek Canal virus, and New York virus, while South American members include Andes virus and Laguna Negra virus ([@B1]--[@B5]). Although HPS was first diagnosed as a clinical entity in 1993 in response to the four corners outbreak ([@B6]), retrospective studies have identified hantavirus-associated fatalities as early as 1978 ([@B7]). HPS cases have been reported in 34 states with the majority occurring in the Southwestern states; however, several have been reported in the Northwestern and Midwestern states. Through April 2014, the Center for Disease Control and Prevention has confirmed 639 total cases of HPS in the U.S., with the majority occurring in New Mexico (94 cases), Colorado (81 cases), and Arizona (72 cases) ([@B8]). Although the prevalence of HPS is low in the U.S., 36% of all reported HPS cases have resulted in death, underscoring the potential impact to public health.

Clinically, HPS manifests with fatigue, fever, muscle pain, headache, dizziness, nausea, and vomiting ([@B9]). Soon after onset, individuals present with bilateral diffuse interstitial edema resembling acute respiratory distress syndrome ([@B10]). Rapidly progressing pulmonary edema, myocardial depression, and hypovolemia are the leading cause of death ([@B11]). There is no specific treatment for HPS; therefore, medical care is mainly supportive with early diagnosis resulting in more successful outcomes.

Hantaviruses do not produce a visible cytopathic effect; consequently, it is believed that cytokines produced by infected cells either directly or indirectly lead to a compromised endothelial monolayer, which in turn, leads to vascular leakage. Indeed, increased numbers of cytokine-producing cells have been observed in lung and spleen tissue of HPS cases ([@B12]). We as well as others have demonstrated that endothelial cells produce the chemokines, CCL5 and CXCL10, when infected with Sin Nombre virus ([@B13], [@B14]). These cytokines are strong chemoattractants for mononuclear leukocytes including monocytes, lymphocytes, and natural killer (NK) cells ([@B15], [@B16]). Expression of these chemokines may explain the postmortem observation of monocytic interstitial pneumonia in fatal HPS cases; however, it remains to be determined whether these chemokines are expressed during active HPS. In contrast to CCL5 and CXCL10 and atypical of most viral infections, *in vitro* culture studies show that only a slight upregulation of type I interferon (IFN) is observed when endothelial cells are infected with hantaviruses. These data are also consistent with clinical observations that suggest that a robust IFN-α response is not characteristic of hantavirus infection ([@B17], [@B18]).

Although limited data exist regarding cytokine expression in subjects with HPS, a study by Borges et al. evaluated the concentrations of 11 serum analytes by ELISA. A cytokine profile was reported that defined the differential expression of a selected number of Th1 and Th2 cytokines ([@B19]). Specifically, they observed significantly elevated levels of IL-6, IFN-γ, sIL-2R, TNF-α, and decreased IL-10 when compared to controls, suggesting that activation of Th1 and Th2-type immune responses are involved. While ELISA is commonly used for such studies, it has limitations such as the necessity of a large sample volume and this issue is compounded when one wishes to analyze multiple analytes. High-throughput multiplex analysis by Luminex xMAP technology allows the simultaneous detection and quantitation of many analytes and uses a small amount of serum or plasma. In the present study, we utilized Luminex xMAP technology to conduct a comprehensive evaluation of 68 different cytokines, chemokines, angiogenic, and growth factors (hereafter referred to collectively as cytokines) in subjects with HPS, including 38 cytokines previously not investigated in association with this disease. Changes in 40 cytokines were detected in the serum of subjects with HPS when compared to healthy controls; 25 cytokines were significantly upregulated while15 were downregulated. A subset of these cytokines known to influence the migration of mononuclear effectors was upregulated, as were cytokines known to play a role in lung microbial defense and tissue repair. Another subset of cytokines associated with thrombocyte counts and function was downregulated. This study corroborates clinical findings and extends our current knowledge by providing a more comprehensive basis for the immune responses and morphology observed in laboratory and histological findings in subjects with HPS.

Materials and Methods {#S2}
=====================

Subjects {#S2-1}
--------

Twelve clinical diagnostic serum specimens collected from 2008 to 2012 by the Nevada State Health Laboratory (NSHL) and with a confirmed diagnosis of HPS were utilized in this study. The NSHL serves as a regional reference laboratory and routinely screens subjects suspected of having HPS, by the presence of anti-hantavirus antibodies. These deidentified diagnostic specimens were deemed to be exempt from IRB approval by the University of Nevada (UNR), Research Integrity Office (Reference \#616225-1) as meeting the exemption criteria defined by the Department of Health and Human Services under Human Subject Research Code 45 CFR 46.102(f). Information of each HPS case was limited to diagnosis, gender, and antibody titer range. Forty-two serum samples from healthy individuals collected under informed consent were used as controls (Human subjects protocol \# B12-031). Control subjects were chosen to be consistent with published demographics of typical HPS cases regarding age and gender (male to female ratio of 54--46%, respectively, and mean age of 39.4 years) ([@B20]).

HPS screening {#S2-2}
-------------

Serum anti-hantavirus antibody titers were evaluated by ELISA, according to the methods described by Feldmann et al. ([@B21]). Serum dilutions (1:100--1:6400) were tested for the presence of anti-hantavirus IgG and IgM using recombinant nucleocapsid protein supplied by the United States Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA). Subjects with antibody titers greater than twofold above that of negative controls were considered positive.

Multiplex analysis {#S2-3}
------------------

The levels of serum cytokines were analyzed using Bio-Plex (Bio-Rad, Hercules, CA, USA) multiplex magnetic bead-based antibody detection kits following the manufacturer's instructions. The Bio-Plex Pro Human Chemokine Panel (40-Plex); Bio-Plex Pro Human Th17 Cytokine Panel; Bio-Plex Pro Human Cytokine 27-plex Panel; and Bio-Plex Human Cytokine 21-plex Panel were used for analysis of a total of 68 analytes. Fifty microliters of serum from each respective case and control was analyzed using a Luminex 200 analyzer with MasterPlex CT control software and MasterPlex QT analysis software (MiraiBio, San Bruno, CA, USA). Standard curves for each analyte were generated using standards provided by manufacturer. Serum samples from HPS cases were heat inactivated and tested for the presence of infectious virus prior to Luminex analysis. The effect of heat inactivation on cytokine stability was evaluated and those that could not be normalized were excluded from analysis.

Statistical analysis {#S2-4}
--------------------

Mann--Whitney non-parametric analysis was utilized to identify differences in medians between HPS cases and controls. In addition, we performed classification analysis using the tree-based ensemble machine learning algorithm Random Forest (RF) ([@B22]). For this analysis, 500 random trees were built using six predictors for each node, and auto-bootstrap out-of-bag sampling was used for testing the model as previously described ([@B23]).

Results {#S3}
=======

Anti-hantavirus titer in HPS serum {#S3-5}
----------------------------------

Twelve serum samples from subjects suspected of having hantavirus infection were tested for the presence of anti-hantavirus IgG and IgM antibodies. Antibody titers twofold greater than those of the control samples were considered diagnostic for hantavirus infection (Table [1](#T1){ref-type="table"}). Previous reports suggest that anti-hantavirus IgM and IgG change with disease progression ([@B24], [@B25]). As reported by MacNeil and coworkers, early stage HPS is characterized by high IgM titers that peak within 11--14 days after onset whereas cases with early stage HPS often have no SNV-specific IgG titer ([@B24]). In contrast to IgM titers, median IgG titers typically displayed an increasing trend for a longer interval after the onset of disease. In light of the deidentified nature of our HPS cases, we used antibody titers to assess the stage of their illness. Six of our cases had high serum titer of IgM while IgG levels were low or undetectable, indicative of early stage disease. For the remaining six cases, high serum titers were observed for both IgG and IgM, consistent with late onset HPS.

###### 

**Antibody titer in serum from HPS cases**.

  Subject   IgM titer   IgG titer   Stage
  --------- ----------- ----------- -------
  1         \>6400      \<400       Early
  2         \>6400      \<400       Early
  3         \>6400      \<400       Early
  4         \>400       Negative    Early
  5         \>400       Negative    Early
  6         \>400       Negative    Early
  7         \<6400      \>6400      Late
  8         \<6400      \>6400      Late
  9         \<6400      \>6400      Late
  10        \<6400      \>6400      Late
  11        \<6400      \>6400      Late
  12        \<6400      \>6400      Late

Differential expression of serum cytokine in HPS cases {#S3-6}
------------------------------------------------------

A total of 68 serum cytokines were measured for HPS cases and controls (Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}). To the best of our knowledge, 38 of these cytokines were previously uninvestigated in the context of HPS (indicated by an asterisk in Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}). A significant increase in the serum levels of 25 of 68 (36.7%) cytokines were observed for the HPS cases when compared to healthy controls (Table [2](#T2){ref-type="table"}). The greatest difference was observed for IL-6, CXCL10, CX3CL1, MIF, and MIG, all of which were upregulated fivefold over those of controls (*p* \< 0.001). In contrast, 15 of 68 (22.1%) cytokines were downregulated in HPS cases when compared to controls (Table [3](#T3){ref-type="table"}), the greatest differences were observed for CXCL12, CCL21, CCL22, CCL27, and sCD40L (*p* \< 0.001). Additionally, the majority of downregulated cytokines belonged to the homeostatic and inflammatory chemokine family. Of the 68 cytokines investigated, 28 (41.2%) were not statistically different when comparing cases and controls (Table [4](#T4){ref-type="table"}).

###### 

**Cytokines upregulated in HPS cases compared to healthy controls**.

  Analyte                    Case (pg/mL), *n* = 12   Control (pg/mL), *n* = 41   *p* Value
  -------------------------- ------------------------ --------------------------- -----------
  Upregulated In HPS serum                                                        
  IL-1α                      537.7 ± 95.0             179.12 ± 15.7               0.0001
  IL-2RA                     455.3 ± 84.6             177.3 ± 7.3                 0.0001
  IL-2                       11.7 ± 3.6               4.7 ± 0.8                   0.005
  IL-3                       415.1 ± 86.4             140.5 ± 11.4                0.0001
  IL-6                       87.9 ± 22.7              10.8 ± 2.0                  0.0001
  IL-10                      49.2 ± 31.5              15.7 ± 1.1                  0.05
  IL-12(p40)                 927.3 ± 175.1            280.7 ± 22.9                0.0001
  IL-17A\*                   23.3 ± 6.8               7.5 ± 0.2                   0.0001
  IL-17F\*                   74.3 ± 19.3              17.9 ± 4.8                  0.0001
  IL-18\*                    1651.6 ± 495.1           803.6 ± 66.7                0.006
  IL-22\*                    42.1 ± 12.1              22.7 ± 0.5                  0.004
  CCL23\*                    705.9 ± 102.5            375.7 ± 37.6                0.0004
  CXCL10                     2834.2 ± 913.5           197.8 ± 18.8                0.0001
  CX3CL1\*                   1456.6 ± 321.2           241.3 ± 13.2                0.0001
  GM-CSF                     55.3 ± 9.7               14.2 ± 2.5                  0.0001
  M-CSF                      4811.7 ± 167.7           415.1 ± 26.5                0.0001
  VEGF                       179.2 ± 122.7            48.8 ± 6.1                  0.05
  MIF\*                      4779.9 ± 2229            540.6 ± 70.5                0.001
  CXCL9\*                    2702.7 ± 891             355.0 ± 93.0                0.0001
  TNFβ                       227.9 ± 26               147.9 ± 12.9                0.007
  IFNα                       191.9 ± 26.2             123.6 ± 9.8                 0.005
  LIF\*                      346.7 ± 40.9             216.9 ± 10.7                0.0001
  b-NGF\*                    122.0 ± 13.8             98.3 ± 3.9                  0.03
  SCF\*                      1180.8 ± 233.9           469.3 ± 30.9                0.0001
  TRAIL\*                    391.9 ± 82.4             266.7 ± 14.8                0.02

###### 

**Cytokines downregulated in HPS cases compared to healthy controls**.

  Analyte                      HPS (pg/mL), *n* = 12   Control (pg/mL), *n* = 41   *p* Value
  ---------------------------- ----------------------- --------------------------- -----------
  Downregulated in HPS serum                                                       
  CCL1\*                       41.7 ± 0.3              43.3 ± 0.4                  0.03
  CCL5                         1210.5 ± 230            5520.3 ± 670                0.001
  CCL11                        18.5 ± 0.9              47.1 ± 2.6                  0.0001
  CCL13\*                      37.1 ± 10.2             135.0 ± 14.1                0.0005
  CCL17\*                      70.4 ± 31.5             241.4 ± 22.3                0.0004
  CCL19\*                      156.2 ± 58.9            418.5 ± 38.1                0.001
  CCL21\*                      979 ± 193               3504.6 ± 119                0.0001
  CCL22\*                      276.2 ± 101             1112.8 ± 60.4               0.0001
  CCL24\*                      356.7 ± 93.8            597.8 ± 49.5                0.02
  CCL26\*                      16.4 ± 2.5              27.6 ± 1.9                  0.005
  CCL27\*                      319.8 ± 65.7            1411.4 ± 79.9               0.0001
  CXCL6\*                      25.7 ± 44               48.2 ± 2.3                  0.0002
  CXCL12\*                     166.7 ± 32.7            2367.3 ± 104.3              0.0001
  CXCL16\*                     183.4 ± 44.0            618.3 ± 27.9                0.0001
  sCD40L                       89.3 ± 54.4             2014.2 ± 128                0.0001

###### 

**No significant difference in cytokine expression between HPS and healthy controls**.

  Analyte    HPS, *N* = 12 (pg/mL)   Healthy control, *n* = 41 (pg/mL)   *p* Value
  ---------- ----------------------- ----------------------------------- -----------
  IL-1       4.59 ± 0.1              4.8 ± 0.2                           0.52
  IL-1RA     93.7 ± 50.7             50.4 ± 7.4                          0.15
  IL-1β      2.7 ± 0.1               7.9 ± 1.9                           0.1
  IL-4       64.9 ± 5.2              78.4 ± 5.2                          0.18
  IL-5\*     6.3 ± 0.6               5.9 ± 0.1                           0.27
  IL-7       5.3 ± 2.1               5.5 ± 0.5                           0.9
  IL-9\*     9.9 ± 1.7               19.7 ± 11.9                         0.66
  IL-13      8.7 ± 0.5               8.9 ± 0.34                          0.59
  IL-15      9.7 ± 4.1               5.7 ± 0.07                          0.07
  L-16\*     252.2 ± 53.4            317.2 ± 40.9                        0.4
  IL-21      30.7 ± 8.7              30.1 ± 6.0                          0.96
  IL-23      102.6 ± 25.3            95.1 ± 17.4                         0.83
  IL-25\*    1.6 ± 0.3               2.4 ± 0.3                           0.2
  IL-31\*    18.5 ± 3.2              21.4 ± 2.2                          0.49
  IL-33\*    402.6 ± 125.7           723.3 ± 100.0                       0.11
  CCL3       18.3 ± 3.7              43.9 ± 9.5                          0.15
  CCL7\*     196.9 ± 27              169.1 ± 23.1                        0.55
  CCL8       75.8 ± 11.3             95.8 ± 6.8                          0.15
  CXCL1\*    215.9 ± 34.9            232.4 ± 13.4                        0.6
  CXCL2\*    236.8 ± 37.7            302.1 ± 25.3                        0.2
  CXCL5\*    1085.8 ± 230.1          798.1 ± 90.6                        0.43
  CXCL11\*   23.5 ± 5.2              41.3 ± 10                           0.35
  FGF\*      14.8 ± 1.3              20.7 ± 2.7                          0.24
  GCSF       26.2 ± 13               26.4 ± 3.3                          0.98
  HGF\*      973.7 ± 284.6           869.9 ± 82.4                        0.64
  IFNγ       20.1 ± 5.0              15.4 ± 1.6                          0.24
  DCGF-β\*   6605.8 ± 1808           4692.7 ± 353.1                      0.1
  PDGF       889.9 ± 302             1095.5 ± 62.1                       0.29

Analysis of serum cytokines in early vs. late stage HPS {#S3-7}
-------------------------------------------------------

In order to investigate the possibility that differential expression of cytokines occurs between subjects with early and late stage HPS, we compared these two subgroups with each other and to healthy controls. Surprisingly, we observed only five cytokines to be differentially expressed between the two subgroups of HPS cases (Table [5](#T5){ref-type="table"}). Of these, median IL-33 and CXCL6 levels were greater in the early stage subjects whereas median CCL23, CXCL1, and TNF-β were greater in the late stage subjects. As expected, differences in cytokine expression between subgroups and controls were consistent with differences observed between total HPS cases and controls (data not shown).

###### 

**Serum cytokine profile during early and late stages of HPS**.

  Analyte      HPS early (pg/mL)   HPS late (pg/nL)   Control (pg/mL)   *p* Value\*   *p* Value\*\*   *p* Value\*\*\*
  ------------ ------------------- ------------------ ----------------- ------------- --------------- -----------------
  IL-1α        316.3 ± 60.4        545 ± 98.1         179.12 ± 15.7     0.006         0.0001          
  IL-2RA       345.5 ± 92.5        454.9 ± 44.2       177.3 ± 7.3       0.001         0.0001          
  IL-2         11.9 ± 5.5          10.1 ± 4.6         4.7 ± 0.8                       0.02            
  IL-3         269.3 ± 39.8        331.6 ± 87.2       140.5 ± 11.4      0.0004        0.0002          
  IL-6         50.4 ± 30.5         109.9 ± 25.9       10.8 ± 2.0        0.003         0.0001          
  IL-10        34.6 ± 12.4         14.6 ± 0.5         15.7 ± 1.1                      0.02            
  IL-12(p40)   613.9 ± 77.3        815.1 ± 196.3      280.7 ± 22.9      0.0001        0.0001          
  IL-15        13.8 ± 7.5          5.6 ± 0.4          5.7 ± 4.1         0.008                         
  IL-17A       20.1 ± 6.2          24.6 ± 10.5        7.5 ± 0.2         0.0001        0.001           
  IL-17F       61.0 ± 24.8         52.7 ± 10.7        17.9 ± 4.8        0.009         0.03            
  IL-22        32.2 ± 12.5         55.8 ± 24.4        22.7 ± 0.5        0.0005                        
  IL-33        651.5 ± 179.2       74.5 ± 19.3        723.3 ± 100                                     0.03
  CCL5         1339.8 ± 409.3      1168.7 ± 182.5     5520.3 ± 670      0.02          0.05            
  CCL11        20.0 ± 1.3          17.5 ± 0.6         47.1 ± 2.6        0.0002        0.0009          
  CCL17        124.1 ± 51.5        17.7 ± 5.6         241.4 ± 22.3                    0.003           
  CCL19        250.1 ± 64.4        126.3 ± 32.9       319.6 ± 38.1                    0.02            
  CCL21        732.9 ± 136.8       1185.5 ± 303.1     3504.6 ± 119      2.8E-11       0.0001          
  CCL22        458.6 ± 159.4       108.5 ± 39.9       1112.8 ± 60.4     0.0004        0.0001          
  CCL23        489.8 ± 112.4       990.7 ± 122.7      375.7 ± 37.6                    0.0001          0.02
  CCL24        229.5 ± 53.3        608.2 ± 180.2      597.8 ± 49.5                    0.007           
  CCL26        18.5 ± 4.3          13.9 ± 2.6         27.6 ± 1.9                      0.03            
  CCL27        306.4 ± 91.9        391.2 ± 97.1       1411.4 ± 79.9     0.0001        0.0003          
  CXCL1        470.0 ± 50.8        954.3 ± 176.8      232.4 ± 13.4                    0.03            0.01
  CXCL5        2005.6 ± 1072.8     225.0 ± 49.9       708.1 ± 90.6      0.02                          
  CXCL6        32.9 ± 8.3          21.3 ± 10.9        48.2 ± 2.3                      0.04            0.003
  CXCL10       2785.2 ± 146.2      3843.1 ± 1266      197.8 ± 18.8      0.0001        0.0001          
  CXCL12       191.1 ± 47.2        181.0 ± 42.6       2367.3 ± 104.3    0.0001        0.0001          
  CXCL16       201.5 ± 73.8        175.2 ± 29.9       618.1 ± 27.9      0.0001        0.0001          
  CX3CL1       1020.4 ± 440.6      1710.3 ± 309.1     241.3 ± 13.2      0.0001        0.0001          
  GM-CSF       67.3 ± 9.7          43.6 ± 16.6        14.2 ± 2.5        0.0001        0.005           
  DCGF-β       4611 ± 1036.1       11215.6 ± 3269     4692.7 ± 353.1                  0.0002          
  LIF          253.3 ± 39.1        386.8 ± 50.4       216.9 ± 10.7                    0.0001          
  M-CSF        1721.7 ± 475.2      3563.8 ± 1221.1    415.1 ± 26.5      0.0001        0.0001          
  MIG          2924.6 ± 1596.1     3152.6 ± 2746.3    355.0 ± 93.0      0.0003        0.0001          
  MIF          1977.3 ± 540.6      666.2 ± 200.9      540.6 ± 70.5      0.008         0.0001          
  sCD40L       157.8 ± 85.1        15.7 ± 4.3         2014.2 ± 128      0.0001        0.0001          
  SCF          798.8 ± 207.6       1390.8 ± 443.1     469.3 ± 30.9      0.006         0.0001          
  TNFβ         167 ± 16.4          226.9 ± 16.1       147.9 ± 12.9                                    0.04
  VEGF         286.5 ± 48.8        101.4 ± 28.5       48.86.1           0.01          0.02            

*\*p value early phase to control; \*\*p value late phase to control; \*\*\*p value early to late phase*.

Classification of cytokines by importance {#S3-8}
-----------------------------------------

Given the complex interactions of cytokines with immune and non-immune cells, clarification of how distinct cytokines contribute to a pathological situation is often difficult to resolve. In order to provide insight into this issue, we implemented the machine logic algorithm RF to analyze our data set and potentially identify the most important cytokines that define this disease. For our analysis, 500 random decision trees were constructed with six predictors at each node, and auto-bootstrap out-of-bag sampling was implemented to test the accuracy of model. This model accurately identified HPS cases with 100% specificity and 73.81% sensitivity (Table [6](#T6){ref-type="table"}). The 10 most significant cytokines for delineating HPS in decreasing order of importance are: M-CSF, CXCL16, sCD40, CXCL12, CCL22, IL-1a, CCL21, IL-12p40, CCL17, and IL-1b.

###### 

**Random forest analysis of serum cytokines in HPS vs. controls**.

  Variable     Score (%)   Changes in HPS serum   Variable   Score (%)   Changes in HPS serum
  ------------ ----------- ---------------------- ---------- ----------- ----------------------
  M-CSF        100.0000    Upregulated            IL-17F     19.4733     Upregulated
  CXCL16       98.7888     Downregulated          CCL3       19.1369     Unchanged
  sCD40L       96.8968     Downregulated          CCL1       18.8358     Downregulated
  CXCL12       85.5322     Downregulated          CXCL11     18.5085     Unchanged
  CCL22        78.4301     Downregulated          DCGFB      17.9953     Unchanged
  IL-1α        74.0061     Upregulated            IL-4       17.7238     Unchanged
  CCL21        70.3732     Downregulated          IL-25      17.4077     Unchanged
  IL-12(p40)   62.9938     Upregulated            IL-33      16.6915     Unchanged
  CCL17        62.8689     Downregulated          CCL7       16.5016     Unchanged
  IL-1β        61.4314     Unchanged              TRAIL      15.7741     Upregulated
  CCL5         61.0088     Downregulated          IL-9       14.3617     Unchanged
  IL-3         58.5351     Upregulated            IL-18      12.0276     Upregulated
  CCL13        58.0210     Downregulated          IL-7       10.5668     Unchanged
  CXCL9        52.4830     Upregulated            IL-22      10.2808     Upregulated
  CXCL10       50.3664     Upregulated            CXCL2      9.3174      Unchanged
  CCL11        48.5759     Downregulated          MIF        8.8718      Upregulated
  CCL27        46.5450     Downregulated          IL-16      8.8434      Unchanged
  CXCL5        46.0115     Unchanged              b-NGF      7.9004      Upregulated
  CX3CL1       45.6097     Upregulated            IL-31      7.0565      Unchanged
  GM-CSF       43.1944     Upregulated            IL-10      6.3552      Upregulated
  IFNα         41.2777     Upregulated            CCL8       6.1227      Unchanged
  LIF          40.7034     Upregulated            IL-17A     5.3501      Upregulated
  CCL24        39.4832     Downregulated          INFG       4.9877      Unchanged
  IL-2RA       38.9993     Upregulated            GCSF       4.4335      Upregulated
  PDGF         36.2886     Unchanged              IL-1       4.1642      Unchanged
  CCL19        34.6337     Downregulated          FGF        4.0244      Unchanged
  IL-6         31.5406     Upregulated            HGF        3.9312      Unchanged
  CXCL6        30.4604     Downregulated          IL-1RA     3.5669      Unchanged
  IL-15        25.5225     Unchanged              CXCL1      3.3770      Unchanged
  TNFβ         24.6500     Upregulated            IL-5       2.6487      Unchanged
  SCF          24.2768     Upregulated            IL-23      2.2930      Unchanged
  IL-2         22.9123     Upregulated            VEGF       0.9825      Upregulated
  CCL26        21.2675     Downregulated          IL-13      0.0038      Unchanged
  CCL23        20.7866     Upregulated                                   

Discussion {#S4}
==========

The microvascular endothelium is principal target of hantavirus infection in humans and its infection in lung tissue results in significant pathology ([@B26]). Infection of endothelial cells leads to increased vascular permeability without an observable cytopathic effect; therefore, the pathogenesis of HPS is likely indirect with immune responses, such as cytokine production, playing an important role. The cytokines that we observed to be upregulated in the serum of HPS cases are involved in a number of antiviral defense mechanisms including proliferation, maturation, and activation of leukocytes, as well as survival of leukocytes, and regulation of endothelial monolayer permeability (Table [2](#T2){ref-type="table"}). High levels of IL-1α, IL-6, MIF, and TNF-β suggest a strong proinflammatory milieu in the serum of HPS cases, thus promoting both inflammation and activation of immune responses. We also observed stem cell proliferation factors to be upregulated, potentially promoting the proliferation and differentiation of subsets of immune effector cells. For example, proliferation of myeloid progenitors is strongly supported by IL-3, GM-CSF, and M-CSF. Increased serum concentrations of GM-CSF and M-CSF also suggest proliferation of monocytes and granulocytes (neutrophils, eosinophils, and basophils). Upregulation of the pluripotent factor, SCF, was also observed in association with HPS, suggesting increased proliferation of T lymphocytes, NK cells, and dendritic cells.

We observed a subset of 15 serum cytokines to be downregulated in our HPS cases (Table [4](#T4){ref-type="table"}). Twelve of these cytokines are involved in chemotaxis of lymphocytes, such as B cells, T cells, and NK cells, to sites of infection. Some of these cytokines, including CCL22, CXCL12, and CCL17, are associated with activation of Th2-type immunity and are potent recruiters of Th2 cells to the lungs, as well as activators of pre-B cells ([@B27]--[@B29]). A number of cytokines identified as differentially expressed in the present study are consistent with putative immune responses of lung tissue. For example, we observed the upregulation of serum IL-17F, CXCL16, and IL-22, which are involved in the regulation of leukocyte migration into lung tissue, as well as lung tissue repair ([@B30]--[@B33]). Upregulation of IL-17F has also been observed in the lung tissue of asthmatic cases and its level positively correlated with disease severity ([@B30], [@B34], [@B35]). Overexpression of IL-17F promotes neutrophil infiltration and increased airways sensitivity and thus has a significant impact on lung function ([@B35]). IL-22 is considered a key cytokine for mucosal tissue repair ([@B36]) and by activating antimicrobial responses in lung epithelial cells; it has been shown to be critical for host defense as well. Also, IL-22 promotes lung epithelial cell proliferation ([@B37]) and therefore, based on our analyses, the cytokine profile observed in our HPS cases is consistent with a pulmonary antimicrobial response and subsequent mononuclear cell migration into the lung.

The serum cytokine profile observed in our HPS subjects also suggests a mobilization of mononuclear immune effector cells (Table [2](#T2){ref-type="table"}). IL-12(p40) is an autocrine chemoattractant released by activated macrophages and promotes Th1-type immunity ([@B38], [@B39]). Additionally, serum levels for several potent T lymphocyte and NK chemoattractants were upregulated, including CXCL10, MIG, and CCL23 ([@B15], [@B16], [@B40], [@B41]). MIF and VEGF, which are regulators of mononuclear cell transendothelial migration, were upregulated as well. Migration of leukocytes can also be facilitated by the upregulation of adhesion molecules on the surface of endothelial cells in response to VEGF, IL-1α, and IL-6 ([@B42], [@B43]). MIF and VEGF promote expression of the adhesion molecules, E-selectin, ICAM-1, and VCAM-1, and increase vascular permeability ([@B44], [@B45]). Additionally, VEGF can decrease tight junctions between endothelial cells enabling transmigration of immune effector cells ([@B42], [@B46]). The observed increased serum levels of CXCL1, which may lead to release of VEGF-A from hantavirus-activated endothelial cells, further suggests that upregulation of VEGF plays a role in HPS ([@B47], [@B48]).

Cytokines including CXCL10, MIF, MIG, IL-12(p40), IL-17A, and CCL23 are known to promote proliferation and migration of mononuclear immune cells, such as T lymphocytes, NK cells, monocytes, and dendritic cells ([@B15], [@B49]--[@B51]). Consequently, our data support the previous observations of others whereby mononuclear cell and immunoblasts are the principal cellular infiltrate in the lungs of HPS cases ([@B12]). Nevertheless, the observed cytokine expression also is consistent with the activation and migration of neutrophils. Previous studies suggest that the cytokines, IL-17F, VEGF, CXCL1, GM-CSF, and IL-22, promote neutrophil migration and lung tissue repair ([@B52]--[@B54]). These data corroborate a previous report by Mori et al., who observed low-level neutrophil infiltration in the lungs of HPS case ([@B12]). Interestingly, serum level of CXCL8, the prototype neutrophil chemoattractant, was not significantly elevated in the HPS cases in our study; however, it was identified as one of the top 10 cytokines by our RF analysis, suggesting its expression, or lack thereof, plays an important role in HPS pathology. Our data further suggest that a Th17 shift occurs in HPS ([@B55]). In the presence of IL-23, non-Th17 cells can produce IL-17 ([@B56]); however, we observed no differential expression of serum IL-23 in HPS cases. Therefore, it is likely that activated Th17 lymphocytes were the source of IL-17 in the serum of our HPS cases.

Expression of IL-17 and IL-22 in HPS suggests a developing antimicrobial state in the lung. It has been reported that IL-17 and IL-22 activate β-defensins and the S100 family of proteins ([@B52], [@B57]). *In vivo* studies using knockout mice have demonstrated that IL-17 and IL-22 are crucial for bacterial defense in the lung ([@B58], [@B59]). Furthermore, it has been reported that IL-17R signaling is mandatory for the establishment of an antibacterial response to *M. pneumoniae*, systemic fungal infection, *B. fragilis*, and *E. coli* ([@B60]--[@B63]). Consistent with this statement, a protective role for IL-22 was recently reported for experimental influenza A virus infection ([@B64]).

We also observed a subset of cytokines involved in the regulation of platelet counts and function to be downregulated in the serum of our HPS subjects, including sCD40L, CCL5, CCL22, and CXCL12 (Table [3](#T3){ref-type="table"}). Consistent with our observations and the pathophysiology of HPS, CXCL12 and CCL22 act on platelets to rapidly stimulate their adhesion ([@B65]), and CCL5 and sCD40L are released by activated platelets ([@B66]--[@B68]). Wenzel and coworkers reported that serum levels of sCD40L closely correlate with platelets counts and that they are increased upon thrombocyte transfusion ([@B69]). Viallard et al. also reported a correlation between thrombocyte counts and serum sCD40L, implying that it may be used as a surrogate marker for platelet counts ([@B66]). Decreased thrombocyte counts are also well documented in association with HPS ([@B2], [@B70]) and our observation of downregulated sCD40L presents a potential biomarker for the thrombocytopenia. Notwithstanding, decreased serum CCL22 might also reflect the development of the thrombocytopenia observed in HPS cases. It has been shown that CCL22 is capable of aggregating platelets in the presence of low concentrations of thrombin or adenosine diphosphate (ADP), and can rapidly stimulate platelets adhesion ([@B65]). It is noteworthy that endothelial cells do not produce this cytokine; dendritic cells are the main source of CCL22 ([@B71]). Therefore, the thrombocyte aggregation and depletion observed in HPS may be the result of cytokine-driven immune responses.

Serum levels of CCL21 and CCL27 were also downregulated in the serum of our HPS subjects. These cytokines have tissue-specific activity; for example, CCL21 orchestrates dendritic cell and T cell trafficking to the lymph nodes ([@B72]--[@B74]) and CCL27 regulates migration of immune effector cells to the skin ([@B75]). Taken together, these findings suggest that the cytokines expressed during HPS promote lung tissue infiltration while reducing leukocyte trafficking to other organs and tissues.

In order to investigate the contribution of each respective cytokine to the disease process, we conducted classification analysis by RF. Of the 10 most important cytokines identified by this analysis, 3 were significantly upregulated, as determined by Mann--Whitney analysis; however, we also observed 6 to be downregulated. This observation underscores the importance of cytokine inhibition in the disease process and further suggests that depressed serum cytokine expression may be an important biomarker for monitoring disease progression.

Overall, the majority of downregulated serum cytokines were associated with Th2-type immune activation; these included CCL21, CCL17, CCL13, and CCL11. Furthermore, the cytokines significantly upregulated in HPS cases were those promoting Th1-type immunity; these included CXCL9, CXCL10, and IL-12(p40). The cytokines M-CSF, CXCL12, IL-3, LIF, GM-CSF, CCL24, which facilitate activation, differentiation, and bone marrow mobilization of myeloid progenitors, were also identified by RF analysis to differentiate HPS cases from controls. RF analysis further identified chemokines associated with platelet aggregation as important in differentiating cases from controls. Interestingly, sCD40L and CXCL12 were ranked, respectively, as the third and fourth most import cytokine in our RF analysis. Chemokines, such as sCD40L, CXCL12, and CCL17, which are stored in platelet granules, are released upon platelet aggregation, a process that is critical in HPS pathology ([@B2], [@B76]--[@B78]). Accordingly, nadir platelet counts in HPS may explain low serum CXCL1, CCL17, and sCD40. Taken together, RF analysis supports the supposition that HPS pathogenesis may be characterized by Th1-type immune responses and thrombocytopenia.

In summary, our data suggest that HPS is characterized by a serum cytokine profile that is consistent with putative immune responses in lung tissue. Strong activation of mononuclear immune effectors including T lymphocytes, NK cells, and dendritic cells is also suggested by this cytokine profile. Additionally, our data imply that decreased counts and increased aggregation of thrombocytes in HPS might be explained in part by the immune response to viral infection. Lastly, to the best of our knowledge, our data provide the first evidence of Th17 lymphocyte activation in association with HPS. The data presented in this study are suggestive of putative *in vivo* immune mechanisms and may identify the role of these cytokines in HPS pathophysiology; however, future studies using animal models would be necessary to definitively confirm their involvement.
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